{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:35Z","timestamp":1753892015486,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Thymic squamous cell carcinoma (TSCC) is a rare yet aggressive tumor associated with a dismal prognosis. The patient, a 76-year-old male, presented with symptoms of fatigue, bloody sputum and dyspnea. Computed tomography (CT) and positron emission tomography\/computed tomography (PET\/CT) scans demonstrated a significant mass in the chest, accompanied by metastasis to adjacent lymph nodes. Vascular ultrasound and CT angiography both indicated thrombosis in the jugular, innominate, and left subclavian veins. A CT-guided needle biopsy subsequently confirmed the diagnosis of TSCC. The patient had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 4 and exhibited high PD-L1 expression. The treatment plan entailed multiple administrations of low-dose carboplatin via intrapleural injection, infusions of albumin-bound paclitaxel (ABP), and pembrolizumab. Concurrent anticoagulation and nutritional therapy were also provided. A combination of carboplatin and ABP was administered for six cycles, followed by a single cycle of ABP alone. Subsequently, pembrolizumab was administered for ten cycles. After this, pembrolizumab was temporarily discontinued, and radiation therapy was administered to the primary tumor site and mediastinal lymph nodes. Five weeks later, pembrolizumab therapy was resumed. The patient\u2019s PS has recovered to 0, and have survived for 23 months with a good quality of life. This experience suggests that combining pembrolizumab with low-dose chemotherapy drugs could be a beneficial treatment option for patients with advanced TSCC, poor PS, and high PD-L1 expression.<\/jats:p>","DOI":"10.3389\/fonc.2024.1463772","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:11:03Z","timestamp":1738213863000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report of successful treatment of advanced thymic squamous cell carcinoma with poor performance status using multimodal therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Xianhua","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Kou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongcheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yejin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-center, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592023","article-title":"Thymic squamous cell carcinoma: a population-based surveillance, epidemiology, and end result analysis","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12826","article-title":"Impact of PD-L1, transforming growth factor-beta expression and tumor-infiltrating CD8(+) T cells on clinical outcome of patients with advanced thymic epithelial tumors","volume":"9","author":"Duan","year":"2018","journal-title":"Thorac Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicenter, international, randomized, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodriguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3960\/jslrt.53.9","article-title":"The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma","volume":"53","author":"Hayashi","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4103\/ijmpo.ijmpo_148_16","article-title":"Utility of cluster of differentiation 5 and cluster of differentiation 117 immunoprofile in distinguishing thymic carcinoma from pulmonary squamous cell carcinoma: a study on 1800 nonsmall cell lung cancer cases","volume":"38","author":"Jha","year":"2017","journal-title":"Indian J Med Pediatr Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/bf03257450","article-title":"Pharmacokinetic evaluation of intrapleural carboplatin in patients with Malignant pleural effusion","volume":"6","author":"Esposito","year":"1994","journal-title":"Drug Investig"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.941092","article-title":"Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13014-017-0891-z","article-title":"Exclusion of emphysematous lung from dose-volume estimates of risk improves prediction of radiation pneumonitis","volume":"12","author":"Uchida","year":"2017","journal-title":"Radiat Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx009","article-title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial","volume":"28","author":"Liang","year":"2017","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.718093","article-title":"A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis","volume":"51","author":"Vogelius","year":"2012","journal-title":"Acta Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-induced lung injury: assessment and management","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1463772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:11:05Z","timestamp":1738213865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1463772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":16,"alternative-id":["10.3389\/fonc.2024.1463772"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1463772","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"article-number":"1463772"}}